Carregant...
Selective and noncovalent targeting of RAS mutants for inhibition and degradation
Activating mutants of RAS are commonly found in human cancers, but to date selective targeting of RAS in the clinic has been limited to KRAS(G12C) through covalent inhibitors. Here, we report a monobody, termed 12VC1, that recognizes the active state of both KRAS(G12V) and KRAS(G12C) up to 400-times...
Guardat en:
| Publicat a: | Nat Commun |
|---|---|
| Autors principals: | , , , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Nature Publishing Group UK
2021
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8113534/ https://ncbi.nlm.nih.gov/pubmed/33976200 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-021-22969-5 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|